Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Exact Sciences Cor (EXAS)

Exact Sciences Cor (EXAS)
N/A x N/A N/A x N/A
Post-market by (Cboe BZX)
45.46 -0.14 (-0.31%) 04/25/25 [NASDAQ]
N/A x N/A N/A x N/A
Post-market 44.58 -0.88 (-1.94%) 17:10 ET
Quote Overview for Fri, Apr 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
44.50
Day High
45.79
Open 44.78
Previous Close 45.60 45.60
Volume 1,093,700 1,093,700
Avg Vol 2,778,935 2,778,935
Stochastic %K 78.03% 78.03%
Weighted Alpha -22.15 -22.15
5-Day Change +3.88 (+9.33%) +3.88 (+9.33%)
52-Week Range 39.97 - 72.83 39.97 - 72.83
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 8,444,422
  • Shares Outstanding, K 185,755
  • Annual Sales, $ 2,759 M
  • Annual Income, $ -1,029 M
  • EBIT $ -179 M
  • EBITDA $ 905 M
  • 60-Month Beta 1.14
  • Price/Sales 3.07
  • Price/Cash Flow 8.10
  • Price/Book 3.51

Options Overview Details

View History
  • Implied Volatility 62.35% ( -1.87%)
  • Historical Volatility 56.87%
  • IV Percentile 77%
  • IV Rank 57.67%
  • IV High 77.02% on 07/29/24
  • IV Low 42.36% on 09/03/24
  • Put/Call Vol Ratio 0.12
  • Today's Volume 254
  • Volume Avg (30-Day) 1,053
  • Put/Call OI Ratio 0.84
  • Today's Open Interest 32,418
  • Open Int (30-Day) 40,549

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate -0.37
  • Number of Estimates 5
  • High Estimate -0.14
  • Low Estimate -0.70
  • Prior Year -0.50
  • Growth Rate Est. (year over year) +26.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
39.97 +13.74%
on 04/08/25
Period Open: 45.67
46.48 -2.19%
on 04/07/25
-0.21 (-0.46%)
since 03/25/25
3-Month
39.97 +13.74%
on 04/08/25
Period Open: 55.98
57.26 -20.61%
on 01/27/25
-10.52 (-18.79%)
since 01/24/25
52-Week
39.97 +13.74%
on 04/08/25
Period Open: 58.79
72.83 -37.58%
on 11/05/24
-13.33 (-22.67%)
since 04/25/24

Most Recent Stories

More News
2 Reasons to Like EXAS (and 1 Not So Much)

2 Reasons to Like EXAS (and 1 Not So Much)

EXAS : 45.46 (-0.31%)
Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

Immuno-Oncology Stocks Q4 In Review: Exact Sciences (NASDAQ:EXAS) Vs Peers

NTRA : 153.79 (-0.45%)
EXAS : 45.46 (-0.31%)
INCY : 59.16 (+0.32%)
REGN : 602.64 (+0.48%)
Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

Reflecting On Immuno-Oncology Stocks’ Q4 Earnings: Regeneron (NASDAQ:REGN)

NTRA : 153.79 (-0.45%)
EXAS : 45.46 (-0.31%)
INCY : 59.16 (+0.32%)
REGN : 602.64 (+0.48%)
2 Oversold Stocks Ready to Bounce Back and 1 to Approach with Caution

2 Oversold Stocks Ready to Bounce Back and 1 to Approach with Caution

FSLR : 141.86 (+3.97%)
EXAS : 45.46 (-0.31%)
COTY : 4.97 (-1.39%)
Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

Immuno-Oncology Stocks Q4 Highlights: Incyte (NASDAQ:INCY)

NTRA : 153.79 (-0.45%)
EXAS : 45.46 (-0.31%)
INCY : 59.16 (+0.32%)
REGN : 602.64 (+0.48%)
2 Small-Cap Stocks on Our Watchlist and 1 to Ignore

2 Small-Cap Stocks on Our Watchlist and 1 to Ignore

FVRR : 26.92 (+1.05%)
TENB : 32.98 (+0.83%)
EXAS : 45.46 (-0.31%)
1 Healthcare Stock on Our Watchlist and 2 to Turn Down

1 Healthcare Stock on Our Watchlist and 2 to Turn Down

GH : 48.30 (+1.88%)
EXAS : 45.46 (-0.31%)
EVH : 8.98 (-1.21%)
Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

Natera (NASDAQ:NTRA) Q4 Earnings: Leading The Immuno-Oncology Pack

NTRA : 153.79 (-0.45%)
EXAS : 45.46 (-0.31%)
INCY : 59.16 (+0.32%)
REGN : 602.64 (+0.48%)
1 Stock Under $50 to Target This Week and 2 to Turn Down

1 Stock Under $50 to Target This Week and 2 to Turn Down

SHOO : 20.80 (-1.70%)
EXAS : 45.46 (-0.31%)
IAC : 35.55 (+1.08%)
ReShape Lifesciences, Allarity, Exact Sciences, CVS, AbbVie: 5 Health Care Stocks That Led Retail Message Growth Last Week

Speculation over an impending reverse merger, a Phase 2 trial announcement, comments about upcoming cancer screening tests, a Medicare business deal, and an obesity drug partnership sparked buzz among...

CVS : 65.32 (-0.91%)
EXAS : 45.46 (-0.31%)
ABBV : 186.06 (+3.15%)
RSLS : 0.3650 (-3.95%)
ALLR : 1.1300 (+5.61%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Exact Sciences Corporation is a molecular diagnostics company focused on the early detection and prevention of some of the deadliest forms of cancer. The company has developed an accurate, non-invasive, patient-friendly screening test called Cologuard for the early detection of colorectal cancer and...

See More

Key Turning Points

3rd Resistance Point 47.29
2nd Resistance Point 46.54
1st Resistance Point 46.00
Last Price 45.46
1st Support Level 44.71
2nd Support Level 43.96
3rd Support Level 43.42

See More

52-Week High 72.83
Fibonacci 61.8% 60.28
Fibonacci 50% 56.40
Fibonacci 38.2% 52.52
Last Price 45.46
52-Week Low 39.97

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Value Investing Philosophies: Graham, Buffett, Bogle, and EMH in Perspective